-$0.20 EPS Expected for POINT Biopharma Global Inc. (NASDAQ:PNT) This Quarter

Equities research analysts expect POINT Biopharma Global Inc. (NASDAQ:PNTGet Rating) to report earnings of ($0.20) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for POINT Biopharma Global’s earnings, with estimates ranging from ($0.27) to ($0.16). The firm is expected to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that POINT Biopharma Global will report full year earnings of ($0.89) per share for the current fiscal year, with EPS estimates ranging from ($1.16) to ($0.72). For the next financial year, analysts anticipate that the company will post earnings of ($0.82) per share, with EPS estimates ranging from ($1.08) to ($0.52). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow POINT Biopharma Global.

POINT Biopharma Global (NASDAQ:PNTGet Rating) last released its quarterly earnings data on Friday, March 25th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.10).

Separately, Zacks Investment Research cut POINT Biopharma Global from a “hold” rating to a “sell” rating in a report on Tuesday, March 29th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, POINT Biopharma Global currently has a consensus rating of “Hold” and an average price target of $27.20.

Shares of NASDAQ PNT traded down $0.46 during trading on Friday, hitting $8.51. The company had a trading volume of 241,918 shares, compared to its average volume of 240,051. The stock has a 50 day simple moving average of $7.39 and a 200 day simple moving average of $7.15. POINT Biopharma Global has a 12 month low of $4.25 and a 12 month high of $11.72.

Institutional investors have recently made changes to their positions in the business. Morgan Stanley purchased a new position in POINT Biopharma Global in the third quarter worth approximately $27,000. Cubist Systematic Strategies LLC purchased a new position in shares of POINT Biopharma Global during the third quarter worth $28,000. Penserra Capital Management LLC purchased a new position in shares of POINT Biopharma Global during the fourth quarter worth $25,000. Marshall Wace LLP acquired a new stake in shares of POINT Biopharma Global in the fourth quarter valued at $27,000. Finally, Legal & General Group Plc acquired a new stake in shares of POINT Biopharma Global in the fourth quarter valued at $38,000. 35.95% of the stock is owned by institutional investors and hedge funds.

About POINT Biopharma Global (Get Rating)

POINT Biopharma Global Inc, a late-stage clinical precision oncology company, focuses on the development and commercialization of radiopharmaceuticals for the treatment of cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors.

Featured Stories

Get a free copy of the Zacks research report on POINT Biopharma Global (PNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for POINT Biopharma Global (NASDAQ:PNT)

Receive News & Ratings for POINT Biopharma Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for POINT Biopharma Global and related companies with MarketBeat.com's FREE daily email newsletter.